CI-719 Gemfibrozil cas 25812-30-0

Gemfibrozil is a peroxisome proliferator receptor alpha agonist. The mechanism of action of gemfibrozil is as a Peroxisome Proliferator-activated Receptor alpha Agonist. The chemical classification of gemfibrozil is PPAR alpha. Gemfibrozil is a lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol.

Properties:

Appearance & Physical State: White crystalline powder

Density: 1.044

Boiling Point: 394.7ºC at 760 mmHg

Melting Point: 61-63ºC

Flash Point: 141.6ºC

Refractive Index: 1.511

Vapor Pressure: 6.13E-07mmHg at 25°C

Related Prodcuts:

Moxifloxacin; Moxifloxacin HCL; Fasudil; Fasudil HCL; Pixantrone Maleate; Topotecan Hydrochloride; Irinotecan HCl Trihydrate; Irinotecan; Gemfibrozil; Cicloheximide; Oxaliplatin; Camptothecin; 10-Hydroxycamptothecin; Bendamustine hydrochloride

[1]. Pahan K, et al. Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes. J Biol Chem. 2002 Nov 29;277(48):45984-91. Epub 2002 Sep 18.

[2]. Almad A, et al. The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice. Exp Neurol. 2011 Dec;232(2):309-17.

[3]. Wang JS, et al. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos. 2002 Dec;30(12):1352-6.